17 October 2018 - Express Scripts will cover new migraine drugs from Eli Lilly and Amgen, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers.

The decision represents a setback for Israel-based Teva, which is in the midst of a corporate restructuring and had hoped to capture a sizable share of the multibillion-dollar migraine market. Express Scripts is also taking steps to limit use of the Amgen and Lilly migraine drugs to patients it says are most likely to benefit from them.

Pharmacy benefits managers are taking more aggressive action to lower the cost of prescription drugs for their clients, large employers who pay for health benefits for their workers.

Read Reuters article